Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C

Nephron - Clinical Practice

Volumn 117, Issue 3, 2011, Pages

  Canbakan, Mustafa ^a,f   Senturk, Hakan ^b   Canbakan, Billur ^b   Toptas, Tayfur ^d   Tabak, Omur ^e   Ozaras, Resat ^b   Tabak, Fehmi ^b   Balci, Huriye ^b   Sut, Necdet ^e   Ozbay, Gulsen ^c  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e TRAKYA UNIVERSITY   (Turkey)

^f Harbiye   (Turkey)

Author keywords

AST to platelet ratio index; Chronic hepatitis C; Fibrosis; FibroTest ActiTest; Hemodialysis; METAVIR scoring; Necroinflammatory activity

Indexed keywords

BIOCHEMICAL MARKER;

ACTITEST; ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FIBROTEST; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; THROMBOCYTE;

ADULT; BIOLOGICAL MARKERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NECROSIS; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS;

EID: 77956591216     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320751     Document Type: Article

References (35)

1. Poux JM, Cadranel JF, Fievet P, Dumouchel P, Collot G: Measurement of gamma glutamyl transpeptidase activity: a useful and low-cost tool for the detection of HCV infection in haemodialysed patients. Nephrol Dial Transplant 1998;13:1324. (Pubitemid 28227229)
2. Pereira BJ, Levey AS: Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-999. (Pubitemid 27186522)
3. Rostaing L, Izopet J, Arnaud C, Cisterne JM, Alric L, Rumeau JL, Duffaut M, Durand D: Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. Transplantation 1999;67:556-560. (Pubitemid 29114218)
4. Hanafusa T, Ichikawa Y, Yazawa K, Kishikawa H, Fukunishi T, Kanai T, Shinji Y, Nagano S: Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplant Proc 1998;30:122-124. (Pubitemid 28090335)
5. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002;16:813-828. (Pubitemid 34409005)
6. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999;31(Suppl 1):3-8.
7. Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology 1997;26(Suppl 1):57S-61S. (Pubitemid 27388073)
8. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S: Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005;80:1550-1555. (Pubitemid 43005864)
9. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075. (Pubitemid 32322537)
10. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526. (Pubitemid 36919874)
11. Szasz G, Persinj JP, van der Slik W: A new method for the determination of γ-glutamyl transferase. J Clin Chem Biochem 1976;14:421-427.
12. Bergmeyer HU, Horder M, Rej R: International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Biochem 1986;24:481-489.
13. Tong MJ, Hwang SJ, Lefkowitz M, Lee SD, Co RL, Conrad A, Schmid P, Lo KJ: Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994;9:587-591. (Pubitemid 24364609)
14. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102. (Pubitemid 23203705)
15. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293. (Pubitemid 26260021)
16. Roth D: Hepatitis C virus: the nephrologist's view. Am J Kidney Dis 1995;25:3-16.
17. Pol S: Hepatitis C virus infection in hemodialyzed patients and kidney allograft recipients. Adv Nephrol Necker Hosp 1995;24:315-330.
18. McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99:1396-1400. (Pubitemid 20381876)
19. Perrault J, McGill DB, Ott BJ, Taylor WF: Liver biopsy: complications in 1, 000 inpatients and outpatients. Gastroenterology 1978;74:103-106. (Pubitemid 8248893)
20. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-481.
21. Navarro J, Contreras P, Touraine JL, Freyria AM, Later R, Traeger J: Are 'middle molecules' responsible for toxic phenomena in chronic renal failure? Nephron 1982;32:301-307. (Pubitemid 13175124)
22. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;23:8.
23. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-Allieri A, Rotily M, Sattonet C, Benderitter T, Saint Paul MC, Bonnot HP, Penaranda G, Degott C, Masseyeff MF, Ouzan D: Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006;101:547-555. (Pubitemid 43340931)
24. Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-Muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C: Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C. Gastroenterol Clin Biol 2008;32:858-865.
25. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P, PANFIBROSIS Group: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257-265. (Pubitemid 36286537)
26. Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V: Biomarkers of liver fibrosis. Adv Clin Chem 2008;46:131-160.
27. Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC, Association francaise pour l'etude du foie; Club de reflexion des cabinets et groupes d'hepato-gastro-enterologue; College national des generalistes enseignants; Groupe francophone d'hepatologie gastro-enterologie et nutrition pediatriques; Societe francaise de biologie clinique; Societe francaise de radiologie; Societe nationale francaise de gastro-enterologie: Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 2007;31:504-509.
28. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075. (Pubitemid 32322537)
29. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T: Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003;17:721-725. (Pubitemid 36521078)
30. Kamanna VS, Kashyap ML, Pai R, Bui DT, Jin FY, Roh DD, Shah GM, Kirschenbaum MA: Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 1994;5:193-200. (Pubitemid 24977075)
31. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F, GERMED cyt04 Group: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-133. (Pubitemid 36002476)
32. Bacq Y, Schillio Y, Brechot JF, De Muret A, Dubois F, Metman EH: Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol 1993;17:364-369. (Pubitemid 23189805)
33. Trznadel K, Luciak M, Paradowski M, Kubasiewicz-Ujma B: Hemodialysis and the acute-phase response in chronic uremic patients. Int J Artif Organs 1989;12:762-765. (Pubitemid 20075120)
34. Argilés A, Kerr PG, Mourad G, Mion CM, Atkins RC: Serum alpha 2-macroglobulin in haemodialysis patients: baseline and kinetic studies. Nephrol Dial Transplant 1993;8:1118-1123. (Pubitemid 23322629)
35. Maor Y, Calès P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Pénaranda G, Bar-Meir S, Martinowitz U, Halfon P: Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007;13:722-729. (Pubitemid 350018262)